2 Result: SCYNEXIS
Q2: SCYNEXIS Surpasses Forecasts; Nogin Misses the Mark
August 14th, 2023
SCYNEXIS, Inc. (Nasdaq: SCYX), a biotechnology company, reported second-quarter 2023 earnings of $2.46 per share, surpassing the consensus estimate of $1.55 per share. The company posted quarterly sales of $131.50 million, exceeding analysts' project. Read more
Major Announcements in the Industry: Momentus Secures SpaceX Deal, Clearmind Medicine Receives Trial Approval, and SCYNEXIS Enters Exclusive License Agreement with GSK
May 12th, 2023
In recent updates, several companies have made significant announcements in their respective fields. Here's a breakdown of the latest developments: Momentus Inc. (Nasdaq: MNTS) has entered into a contract with SpaceX, securing a port reservation o. Read more
Want To Find Some News?
News By Industries
Recent Post
-
Earnings Countdown: Lockheed Martin, Stryker, and PACCAR Gear Up
January 26th, 2025Earnings Spotlight: SoFi Technologies, Sanmina, and Nucor Set to Report
January 26th, 2025Global Flag Football League Plans To Host Pro Flag Football Tournament in Las Vegas
January 23rd, 2025Earnings On Deck: Netflix, United Airlines, and Agilysys Gear Up
January 19th, 2025
Member Login